CNCR vs. VB

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and VB (Vanguard Small-Cap ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while VB is a Small Cap Blend Equities fund tracking the CRSP US Small Cap Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.05%/yr for VB.

Performance

CNCR vs. VB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Vanguard Small-Cap ETF (VB). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

VB

• 1D: 0.75%
• 1M: 3.68%
• YTD: 14.91%
• 6M: 16.03%
• 1Y: 31.39%
• 3Y*: 17.31%
• 5Y*: 7.35%
• 10Y*: 11.38%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. VB - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
VB Vanguard Small-Cap ETF	6.87%

CNCR vs. VB - Sectors Allocation Comparison

Sectors	CNCR	VB
Healthcare	96.6%	11.1%
Financial Services	3.3%	12.6%
Basic Materials	-	4.8%
Communication Services	-	3.1%
Consumer Cyclical	-	11.3%
Consumer Defensive	-	3.4%
Energy	-	4.7%
Industrials	-	20.8%
Real Estate	-	7.6%
Technology	-	17.2%
Utilities	-	3.3%

Return for Risk

CNCR vs. VB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VB

VB Risk / Return Rank: 61
VB Sharpe Ratio Rank: 56
VB Sortino Ratio Rank: 57
VB Omega Ratio Rank: 54
VB Calmar Ratio Rank: 69
VB Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. VB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Vanguard Small-Cap ETF (VB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	VB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.94	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.36	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.53	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.44	—

Drawdowns

CNCR vs. VB - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum VB drawdown of -59.56%. Use the drawdown chart below to compare losses from any high point for CNCR and VB.

Drawdown Indicators

	CNCR	VB	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-59.56%	+59.56%
Max Drawdown (1Y) Largest decline over 1 year	—	-8.98%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-25.36%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-28.15%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-42.05%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-8.44%	+8.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	2.43%	—

Volatility

Volatility by Period

	CNCR	VB	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	4.40%	—
Volatility (6M) Calculated over the trailing 6-month period	—	11.73%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	16.27%	-16.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	20.75%	-20.75%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	21.43%	-21.43%

CNCR vs. VB - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than VB's 0.05% expense ratio.

Dividends

CNCR vs. VB - Dividend Comparison

CNCR has not paid dividends to shareholders, while VB's dividend yield for the trailing twelve months is around 1.19%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
VB Vanguard Small-Cap ETF	1.19%	1.33%	1.30%	1.55%	1.59%	1.24%	1.14%	1.39%	1.67%	1.35%	1.50%	1.48%

Frequently Asked Questions

Which ETF is better, CNCR or VB?

On fees, VB is cheaper at 0.05% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or VB?

VB is cheaper with a 0.05% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or VB?

VB has the higher dividend yield at 1.19%, compared with 0.00% for CNCR.

What is the main difference between CNCR and VB?

CNCR is categorized as Health & Biotech Equities, while VB is Small Cap Blend Equities. CNCR tracks Loncar Cancer Immunotherapy Index, while VB tracks CRSP US Small Cap Index. They also come from different issuers: Exchange Traded Concepts and Vanguard. Their fees differ too: 0.79% for CNCR and 0.05% for VB.